Johnson & Johnson Family of Companies

While the world is working to slow the COVID-19 pandemic by social isolation and quarantine, numerous companies globally are working to develop a vaccine against the virus.

The healthcare giant said it selected a lead vaccine candidate and plans to begin human testing in September, with first batches available under potential emergency use authorization in the first part of 2021.

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 30, 2020.

The company isn’t out-and-out saying the drug or any combination drugs with darunavir as a formula might not be effective, but they are saying it’s not based on testing at this time.

No financial terms were disclosed.

As the number of diagnosed cases of COVID-19 continue to increase across the globe and more and more governments are urging citizens to self-quarantine, the pharmaceutical and life sciences industry continues to work toward the development of a vaccine and therapies for the respiratory infection that was declared a pandemic by the World Health Organization last week. Here’s a biopharma industry overview as of late March 16.

The Breakthrough Therapy Designation is based on data from a Phase I trial of JNJ-6372 alone and in combination with lazertinib, a novel third-generation EGFR TKI in adults with advanced NSCLC.

As the coronavirus outbreak that causes COVID-19 escalates, biopharma companies and government agents are working quickly to develop and test a vaccine, although most estimates are it will take 12 to 18 months before it could get to market.

The BioSpace Ideal Employer Report examined aspects regarding the importance of culture within life sciences organizations.